NRAS and melanoma: The prevalence of BRAF and NRAS mutation rates in our study—22.4% and 17.7%, respectively—was higher than the rates of 17.6% and 12.6% reported in a prior study involving a Korean patient with melanoma population utilizing PCR-based assays.31 While mutation prevalence may vary from one study to another and drawing concrete conclusions may be difficult, it is plausible to suggest that the increased prevalence of NRAS and BRAF mutation in our cohort may be attributed to the heightened sensitivity and accuracy of the NGS.